BSE:530239

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Suven Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 530239 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.4%

530239

1.0%

IN Life Sciences

-1.1%

IN Market


1 Year Return

-83.2%

530239

66.2%

IN Life Sciences

-1.4%

IN Market

Return vs Industry: 530239 underperformed the Indian Life Sciences industry which returned 66.9% over the past year.

Return vs Market: 530239 underperformed the Indian Market which returned 0.2% over the past year.


Shareholder returns

530239IndustryMarket
7 Day-0.4%1.0%-1.1%
30 Day-4.0%-0.8%2.0%
90 Day29.1%19.6%6.4%
1 Year-83.2%-83.2%67.1%66.2%0.4%-1.4%
3 Year-77.5%-77.8%157.8%153.3%-3.9%-8.6%
5 Year-82.0%-82.6%160.8%150.7%38.9%28.5%

Price Volatility Vs. Market

How volatile is Suven Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Suven Life Sciences undervalued compared to its fair value and its price relative to the market?

5.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 530239 is unprofitable, so we can't compare its PE Ratio to the IN Life Sciences industry average.

PE vs Market: 530239 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 530239's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 530239 is overvalued based on its PB Ratio (5.2x) compared to the IN Life Sciences industry average (1.7x).


Next Steps

Future Growth

How is Suven Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Suven Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Suven Life Sciences performed over the past 5 years?

-34.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 530239 is currently unprofitable.

Growing Profit Margin: 530239 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 530239 is unprofitable, and losses have increased over the past 5 years at a rate of 34.4% per year.

Accelerating Growth: Unable to compare 530239's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 530239 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (4.5%).


Return on Equity

High ROE: 530239 has a negative Return on Equity (-63.64%), as it is currently unprofitable.


Next Steps

Financial Health

How is Suven Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 530239's short term assets (₹624.4M) exceed its short term liabilities (₹171.4M).

Long Term Liabilities: 530239's short term assets (₹624.4M) exceed its long term liabilities (₹78.7M).


Debt to Equity History and Analysis

Debt Level: 530239's debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: 530239's debt to equity ratio has reduced from 15.5% to 0.6% over the past 5 years.

Debt Coverage: 530239's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 530239's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Suven Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 530239's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 530239's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 530239's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 530239's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 530239 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 530239's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Venkat Jasti (71 yo)

16yrs

Tenure

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S. serves as Chairman of the Board and Managing Director at Suven Pharmaceuticals Limited since November 06, 2019. He serves as Managing Director a ...


CEO Compensation Analysis

Compensation vs Market: Venkat's total compensation ($USD0.00) is below average for companies of similar size in the Indian market ($USD54.82K).

Compensation vs Earnings: Venkat's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Venkateswarlu Jasti
Executive Chairman & CEO16yrsno data0.00079%
₹ 49.3k
Sudharani Jasti
Whole-Time Director31.58yrs₹8.40m0.00079%
₹ 49.3k
M. Kumar
Chief Financial Officer0.75yrno datano data
Shrenik Soni
Company Secretary & Compliance Officer0.75yrno datano data
Kalyani Jasti
President of US Operations10.08yrsno data0.00079%
₹ 49.3k

5.4yrs

Average Tenure

66yo

Average Age

Experienced Management: 530239's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Venkateswarlu Jasti
Executive Chairman & CEO16yrsno data0.00079%
₹ 49.3k
Sudharani Jasti
Whole-Time Director31.58yrs₹8.40m0.00079%
₹ 49.3k
Maripuri Naidu
Independent Non-Executive Director22.08yrs₹270.00k0.0027%
₹ 171.7k
Muddusetty Gopalakrishna
Independent Non-Executive Director7.92yrs₹340.00kno data
Seyed Hasnain
Non-Independent & Non-Executive Director10.5yrs₹190.00kno data
Santanu Mukherjee
Independent Non-Executive Director2.42yrs₹300.00kno data
Jasthi Ananthasai Padmaja
Independent Non-Executive Director1.92yrs₹240.00kno data

7.9yrs

Average Tenure

66yo

Average Age

Experienced Board: 530239's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 530239 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Suven Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Suven Life Sciences Limited
  • Ticker: 530239
  • Exchange: BSE
  • Founded: 1989
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹6.243b
  • Shares outstanding: 127.28m
  • Website: https://www.suven.com

Number of Employees


Location

  • Suven Life Sciences Limited
  • # 8-2-334, SDE Serene Chambers
  • 6th Floor
  • Hyderabad
  • 500034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
530239BSE (Mumbai Stock Exchange)YesEquity SharesININRNov 2001
SUVENNSEI (National Stock Exchange of India)YesEquity SharesININRNov 2001

Biography

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorder ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 12:57
End of Day Share Price2020/10/28 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.